Table 1. Pre-treatment characteristics of strongyloidiasis cohort (n = 691).
| Age (years), median (range) | 63 (15, 92) |
| Male n (%) | 500 (72%) |
| Region of birth n (%) | |
| Pacific Island Countries and Territories (PICT) | 481 (70%) |
| Polynesia | 350 (51%) |
| Samoa | 246 (36%) |
| Tonga | 55 (8%) |
| Cook Islands | 38 (5%) |
| Other Polynesia1 | 11 (2%) |
| Fiji | 130 (19%) |
| Other PICT2 | 1 (0.1%) |
| Aotearoa New Zealand | 88 (13%) |
| Asia | 77 (11%) |
| Southeast Asia | 33 (5%) |
| Indian Subcontinent | 24 (4%) |
| Other Asian Country | 20 (3%) |
| Africa | 10 (1%) |
| Other | 13 (2%) |
| Not available | 22 (3%) |
| Ethnicity n (%) | |
| NZ Māori | 29 (4%) |
| Other | 203 (29%) |
| Pasifika | 459 (66%) |
| District Health Board n (%) | |
| CMDHB | 347 (50%) |
| ADHB | 205 (30%) |
| WDHB | 139 (20%) |
| Immunocompromised | 68 (10%) |
| Diabetes | 381 (55%) |
| Alcohol dependence | 25 (4%) |
| Corticosteroid use within 6 months | 188 (27%) |
| HTLV-1 | |
| Negative | 4 (1%) |
| Not tested | 687 (99%) |
1 Other Polynesia: Niue Island (4), Tuvalu (4), American Samoa (2), Tahiti (1)
2 Other Pacific Island Countries and Territories (PICT): Kiribati (1)